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ttp://dx.doi.org/10.1016/j.ajpath.2012.11.037The movement of leukocytes across endothelium [referred to as diapedesis or transendothelial migra-
tion (TEM)] is a critical step in the inﬂammatory process. Recently, it was demonstrated that treatment
of endothelial cells and monocytes with antibodies against poliovirus receptor (PVR; CD155) and DNAX-
associated molecule-1 (DNAM-1; CD226) arrested monocytes over endothelial junctions and prevented
TEM, suggesting that these molecules are involved in diapedesis. However, nothing was known about
the mechanism by which PVR and DNAM-1 work in TEM. Herein, we show that, similar to endothelial
PECAM interacting with leukocyte PECAM, activation of endothelial PVR with anti-PVR antibodies or
interaction with its ligand, DNAM-1, results in recruitment of the tyrosine phosphatase Shp-2, and this
process is dependent on Src kinases. Furthermore, differential and sequential treatment with blocking
antibodies directed against PVR, DNAM-1, PECAM, and CD99 showed that endothelial PVR and monocyte
DNAM-1 interact at and regulate a step between those regulated by PECAM and CD99. Further studies
demonstrate that PVR resides in the recently identiﬁed lateral border recycling compartment, similar to
PECAM and CD99. These ﬁndings suggest that the localization of adhesion/signaling molecules to the
lateral border recycling compartment and the recruitment of Shp-2 may be common mechanisms for
the regulation of TEM by endothelial cells. (Am J Pathol 2013, 182: 1031e1042; http://dx.doi.org/
10.1016/j.ajpath.2012.11.037)Supported by NIH grant F32 AI084454 (D.P.S.), NIH Medical Scientist
Training Program grant GM07739 (M.A.S.), and NIH grants R01
HL046849 and R37 HL064774 (W.A.M.).
Current address of M.A.S., Department of Pathology, Brigham and
Women’s Hospital, Boston, Massachusetts.Transendothelial migration (TEM; alias diapedesis) is the
putative committed step of the multistep process by which
leukocytes move out of the bloodstream, across the endo-
thelial cell layer, and into target tissue to combat infection
and heal injuries.1,2 This makes it an attractive therapeutic
target for pathological conditions resulting from dysregu-
lated inﬂammation, such as autoimmune arthritis, athero-
sclerosis, and multiple sclerosis. TEM has been regulated in
a quantitatively signiﬁcant way by at least two proteins,
PECAM and CD99, in several in vitro and in vivo sys-
tems.3e5 PECAM and CD99 are expressed on both leuko-
cytes and endothelial cells, and have been shown to operate
via homophilic interaction (ie, leukocyte PECAM with
endothelial PECAM and leukocyte CD99 with endothelial
CD99) in the TEM of neutrophils and monocytes in
response to multiple stimuli.1 Disruption of PECAM or
CD99 homophilic interactions using antibodies against the
appropriate regions of their extracellular domains inhibits
TEM both in vitro and in vivo.4e6stigative Pathology.
.Recently, Reymond et al7 demonstrated a role for the
molecules poliovirus receptor (PVR) and DNAX-associated
molecule-1 (DNAM-1) in TEM, showing that monoclonal
antibodies against either molecule could block the trans-
migration of isolated monocytes across a monolayer of
cultured human umbilical vein endothelial cells (HUVECs).
More recently, Manes and Pober8 used antibodies against
PVR and DNAM-1 to block TEM of effector memory
T cells. However, these studies provided no characteriza-
tion of the mechanism of action or the relationship of
these molecules to other components of the TEM ma-
chinery. PVR (CD155) is a transmembrane immunoglobulin
superfamily member expressed on neurons, epithelium,
endothelium, and monocytes/macrophages, which localizes
Sullivan et alto sites of cell-cell and cell-matrix adhesion.7,9e14 PVR has
primarily been investigated for its role as the key receptor
for poliovirus entry into cells, but has also been reported to
be involved in cell adhesion and motility and cell-mediated
cytotoxicity.15e20 DNAM-1 is a transmembrane immuno-
globulin superfamily member expressed on natural killer
cells, T cells, some B cells, platelets, monocytes, and,
possibly, activated HUVECs.21e25 It has been associated
with natural killer and CD8 T-cell cytotoxicity,21 T-cell de-
velopment,22,25 platelet activation,22,26 and, more recently,
monocyte TEM.7,8
In this study, we sought to characterize the exact role that
PVR and DNAM-1 play in TEM and, perhaps, more
important, the mechanisms through which they act. Herein,
we show that, in a manner analogous to PECAM activation,
the engagement of PVR on the endothelial cell leads to its
phosphorylation by an Src-dependent mechanism, which
leads to localized recruitment and speciﬁc binding of Shp-2.
We also sought to investigate the timing of the PVR and
DNAM-1 interaction during TEM in relation to the roles
played by PECAM and CD99. Having previously described
that PECAM and CD99 function sequentially in TEM,5 we
describe herein that endothelial cell PVR and leukocyte
DNAM-1 interact with each other at a step between those
regulated by PECAM and CD99. We have also previously
shown that PECAM and CD99 localize to the lateral border
recycling compartment (LBRC) and that recycling of this
compartment is essential to the proper functioning of
PECAM and CD99 during TEM.3,27 Herein, we describe
that PVR also localizes to the LBRC. Furthermore, only the
subset of PVR molecules localized to the LBRC is relevant
to TEM, analogous to data previously published for
PECAM and CD99. Our ﬁndings demonstrate that the
process of TEM is regulated at the molecular level by at
least three pairs of molecular interactions functioning at
three sequential steps, yet all involving the membrane
platform of the LBRC.Materials and Methods
All procedures involving human subjects and human
materials were approved by the Institutional Review Board
of Northwestern University Feinberg School of Medicine
(Chicago, IL).Antibodies and Proteins
This study used mouse IgG2a anti-human PECAM clone
hec7,28 mouse IgG1 anti-human CD99 clone hec2,
5 and
mouse IgG2a anti-human VE-cadherin clone hec1,
29 all
produced in the laboratory via hybridoma methods. Rabbit
polyclonal anti-human PECAM(177) was produced as
previously described.4 Anti-PVR antibody (clone D171)
was purchased from Neomarkers/LabVision (Fremont, CA).
AntieDNAM-1 antibody (clone DX11) was purchased1032from BD Biosciences (San Jose, CA). AntieShp-2 antibody
(rabbit polyclonal, sc280) was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-phosphotyrosine
(4G10-platinum) and streptavidinehorseradish peroxidase
(HRP) were purchased from Millipore (Billerica, MA).
Non-speciﬁc mouse IgG and goateanti-rabbit Dylight-549
were purchased from Jackson ImmunoResearch Laborato-
ries (West Grove, PA). Anti-human PECAM clone hec7
conjugated to Alexa Fluor 488 was prepared using a kit
purchased from Invitrogen (Carlsbad, CA). DNAM-1-Fcmut
plasmid DNA was a generous gift from Drs. Christina
Bottino and Claudia Cantoni (Istituto Giannina Gaslini,
Genova, Italy)7; expressed protein was puriﬁed according to
standard techniques previously described.30
Isolation and Culture of Endothelial Cells
HUVECs were isolated from human umbilical cords, as
previously described.28,31 At their second passage, isolated
HUVECs were cultured on either three-dimensional type I
collagen matrices (PureCol; Inamed Biomaterials, Fremont,
CA) or coverslip dishes (Mattek, Ashland, MA) and allowed
to reach conﬂuence. Cells grown on collagen gels were
allowed to mature for 2 to 3 days after this point to ensure
the formation of high-quality basement membranes. Primary
human dermal microvascular endothelial cells (HMVECs)
were purchased from Lonza Group Ltd (Basel, Switzerland)
and cultured in the recommended media, also purchased
from Lonza Group Ltd. PECAM, PVR, and CD99 were all
expressed at intercellular junctions in HMVECs in a manner
identical to HUVECs (data not shown). HMVECs were
used at the second or third passage, and TEM assays
involving HMVECs were performed in the same way as
those described for HUVECs later.
Isolation of Primary Human Leukocytes
Leukocytes were harvested as previously described.31,32
Blood drawn from healthy volunteers was immediately
mixed with 10 mmol/L ﬁnal concentration of EDTA and an
equal volume of HBSS (Mediatech Inc., Herndon, VA) and
then layered over Ficoll-Paque density gradient medium
(GE Healthcare Biosciences AB, Uppsala, Sweden) for the
isolation of peripheral blood mononuclear cells (PBMCs).
After centrifugation at 780  g for 20 minutes, the upper
plasma layer was collected into fresh tubes, and the PBMCs
at the interface were harvested with a ﬂame-polished glass
pipette into a separate tube. The cells were diluted in HBSS,
and both cells and platelet-poor plasma were centrifuged for
10 minutes at 360  g. The cell pellet was resuspended in
the spun plasma and centrifuged for 5 minutes at 235  g.
The resulting pellet was washed two to three times with
HBSS via resuspension and centrifugation for 5 minutes at
235  g. The ﬁnal pellet was resuspended in M199 (Invi-
trogen) containing 0.1% human serum albumin (HSA;
Grifols Biologicals Inc., Los Angeles, CA).ajp.amjpathol.org - The American Journal of Pathology
PVR, PECAM, CD99, and DiapedesisFlow Cytometry
Conﬂuent HUVECs were removed from the tissue culture
plate via light trypsinization. Leukocytes were isolated as
previously described. Pilot studies established that these
procedures did not affect the detection of the antigens exam-
ined herein. Cells in suspension were incubated with the
appropriate primary antibody (including no primary and
irrelevant control isotype-matched antibodies) at 10 mg/mL in
PBS for 1 hour on ice. Cellswerewashed repeatedlywith PBS,
and then incubated with labeled secondary antibody (Alexa
Fluor 488 goat anti-mouse; Molecular Probes, Invitrogen) at
1 mg/mL in PBS for 1 hour on ice. Cells were washed again,
and then assayed on aBDFACSCalibur (BDBiosciences, San
Jose, CA) instrument using BD CellQuest Pro Software
version 5.1 (BD Biosciences).
Immunoﬂuorescence Microscopy
Conﬂuent HUVECs were ﬁxed in 2% paraformaldehyde for
20 minutes, washed three times with PBS, quenched with
75 mmol/L glycine for 15 minutes, and washed three more
times with PBS. Blocking buffer (PBS þ 5% ovalbumin;
Sigma-Aldrich, St. Louis, MO) was added for 30 minutes at
room temperature. Cells were then incubated with primary
antibody at 10 mg/mL in blocking buffer for 1 hour at room
temperature, washed extensively with PBS, and then incu-
bated with secondary antibody (Alexa Fluor 488 goat anti-
mouse) at 4 mg/mL in blocking buffer for 1 hour at room
temperature, protected from light. For the visualization of
Shp-2, cells were permeabilized for 4 minutes with 0.1%
Triton X-100 (Sigma-Aldrich) before blocking. To detect
PECAM, some samples were then incubated with Alexa
Fluor 488econjugated anti-PECAM antibodies (clone hec7)
for 45 minutes and washed before visualization. Samples
that were treated with polystyrene beads were visualized
using an Ultraview VoX imaging system (Ultraview, Wal-
tham, MA) equipped with a Yokogawa CSU-1 spinning
disk (Yokogawa Electric Company, Tokyo, Japan). Images
were acquired with a 488-nm wavelength laser through
a 20 water immersion objective using Volocity software
version 6.2.1 (Perkin Elmer, Waltham, MA). Monolayers
and the samples with glass beads were imaged using
a restoration workstation (Delta Vision 3D; Applied Preci-
sion, Issaquah, WA) equipped with an inverted microscope
(model IX70; Olympus Tokyo, Japan) using a 60 oil
objective.
Electron Microscopy
Antibodies recognizing PVR, PECAM, and VE-cadherin
(clones D171, hec7, and hec1, respectively) were labeledwith
HRP using an EZ-Link Plus activated peroxidase kit (Thermo
Fisher Scientiﬁc, Waltham, MA). Analysis of the labeling
efﬁciency was determined using SDS-PAGE and showed that
the ratio of HRPs per antibody was approximately 1:1.The American Journal of Pathology - ajp.amjpathol.orgAntibodies were incubated with HUVECs grown on 13-mm-
diameter cell cultureetreated Thermanox coverslips (Thermo
Fisher Scientiﬁc) at either 4C or 37C. After incubation for
30 minutes, the monolayers were chilled, washed three times
with ice-cold PBS, and ﬁxed for 10 minutes with 4% glutar-
aldehyde in 100 mmol/L cacodylate buffer, pH 7.4 (Electron
Microscopy Sciences, Hatﬁeld, PA). Monolayers were then
washed three times with PBS and incubated with 10 mg/mL
diaminobenzidine (Sigma-Aldrich) and 0.03% hydrogen
peroxide in PBS for 20 minutes. Monolayers were then
washed three times and ﬁxed again as before. Samples were
embedded according to standard microscopic methods. En
face sections (70 nm thick) were examined using an Tecnai
Spirit electron microscope (FEI Company, Hillsboro, OR).
Glass and Polystyrene Microsphere (Bead) Coating
All incubation steps for the bead coating were performed
using an end-over-end rotator at room temperature, un-
less otherwise indicated. Glass beads (Polysciences, War-
rington, PA), 3 to 10 mm, 2 mg per sample, were washed
three times with 96% ethanol and silanized with 5%
3-aminopropyltriethoxysilane (Sigma-Aldrich) in 96% eth-
anol for 1 hour. The beads were then washed with PBS and
resuspended in 3% glutaraldehyde in PBS and rotated for
2 hours. The beads were washed again and fractionated into
separate tubes, and resuspended in 250 mL of 200 mg/mL of
either bovine serum albumin (BSA) or antibodies against
PVR (clone D171), PECAM (clone hec7), or non-speciﬁc
mouse IgG and incubated for 1.5 hours. To help visualize
the beads, this conjugation reaction was sometimes sup-
plemented with 1 mg/mL of a ﬂuorescently labeled irrele-
vant antibody. The beads were then washed and incubated
with 10 mg/mL of BSA in PBS overnight at 4C.
Amino-functionalized 3 mm polystyrene beads (Poly-
sciences) were washed with PBS and resuspended in 1 mL of
8% glutaraldehyde in PBS for 2 hours. Beads were washed
again, fractionated into separate tubes, and incubated with
300 mL of 300 mg/mL of either BSA or the indicated antibody
for 2 hours. After washing, the beads were blocked with
10 mg/mL BSA for 1 hour. Conjugated beads (both glass and
polystyrene) were stored at 4C in blocking solution for up to
1 week without noticeable loss of efﬁcacy. Beads were
always washed with PBS immediately before use.
For the bead experiments, HUVEC monolayers were
grown on ﬁbronectin-coated coverslip dishes to conﬂuence.
The conjugated beads were diluted into preconditioned
HUVEC media and allowed to settle and bind for either
10 minutes (glass beads) or 20 minutes (polystyrene beads).
Monolayers were then washed with PBS and ﬁxed with 4%
paraformaldehyde, and the indicated proteins were visual-
ized using immunoﬂuorescence. All images within each
experiment were captured under identical settings and pro-
cessed identically using ImageJ software version 1.45s
(NIH, Bethesda, MD) to preserve any differences in relative
intensities.1033
Sullivan et alImmunoprecipitation and Western Blot Analyses
HUVECs were grown to conﬂuence on ﬁbronectin-coated,
6-cm dishes. Monolayers were pretreated for 10 minutes
with 5 mmol/L PP2 [4-amino-5-(4-chlorophenyl)-7-(t-butyl)
pyrazolo(3,4-d)pyramidine] or inactive analogue PP3
[4-amino-7-phenylpyrazolo(3,4-d)pyramidine], both from
EMD Chemicals (Darmstadt, Germany), diluted in condi-
tioned media from a 5 mmol/L stock in dimethyl sulfoxide.
At the start of the assay, media were replaced with condi-
tioned media containing either PP2 or PP3 and 20 mg/mL of
the indicated antibody. After 20 minutes of incubation at
37C with 5% CO2, the media were removed, and the
monolayers were chilled and washed with ice-cold PBS.
To visualize PVR using Western blot analysis, the mono-
layers were then treated with 1 mg/mL Sulfo-NHS-LC-
biotin (Thermo Fisher Scientiﬁc) in PBS on ice for 15
minutes, followed by quenching for 15 minutes with
50 mmol/L glycine in PBS. After washing with PBS, the
cells were lysed in PBS containing 1% NP-40, 1 mmol/L
orthovanadate, 1 protease inhibitor cocktail (P8340;
Sigma-Aldrich), and 1 mmol/L phenylmethylsulfonyl ﬂuo-
ride (Sigma-Aldrich) for 10 minutes on ice. The lysates
were collected and centrifuged at 18,000  g at 4C for 15
minutes in a microfuge. The supernatants were recovered
and incubated with Protein Aeagarose beads loaded with
anti-PVR antibody (D171) for 2 hours at 4C with end-
over-end rotation. The bound beads were washed repeat-
edly with lysis buffer and resuspended in 2 Laemmli
loading buffer with b-mercaptoethanol. The samples were
then boiled for 5 minutes, and equivalent amounts were
loaded onto a 10% polyacrylamide gel and resolved using
SDS-PAGE. Proteins were transferred to PVDF and
detected using standard Western blot analysis techniques.
Blots were ﬁrst probed for phosphotyrosine using 4G10-
platinum and then stripped and reprobed to detect Shp-2,
using rabbit-polyclonal antieShp-2, and PVR, using
streptavidin-HRP.
TEM Assay
TEM assays were performed as previously described.31
Brieﬂy, PBMCs (4  106 per mL) were mixed 1:1 with
either medium alone or dilutions of antibodies to a ﬁnal
concentration of 20 mg/mL. These were then plated onto
conﬂuent HUVEC monolayers grown on hydrated type I
collagen gels and allowed to migrate at 37C in 5% CO2
for 1 hour. The monolayers were washed twice with 1
mmol/L EDTA (Sigma-Aldrich) in HBSS, twice with PBS
supplemented with Ca2þ and Mg2þ, and then ﬁxed in 1%
glutaraldehyde in 0.1 mol/L sodium cacodylate buffer
(Electron Microscopy Sciences). Fixed samples were
stained with modiﬁed Wright-Giemsa stain (Protocol
Hema3; Fisher Diagnostics, Middletown, VA) and moun-
ted onto glass slides for visualization. Imaging was per-
formed with a Zeiss Ultraphot microscope with Nomarski1034optics and a SPOT Insight Color CCD (Diagnostic In-
struments, Inc., Sterling Heights, MI). TEM was analyzed
by manually counting at least 100 cells per collagen gel
and noting their position relative to the endothelial
monolayer (above or below, deﬁning above as any mono-
cyte having most of the cell body on or above the focal
plane of the endothelial cell nuclei). For each ﬁgure
describing TEM, samples were all assayed in the same
experiments and were only separated into panels for
clarity.
Monocyte-Side Function Studies
PBMCs were mixed with reagents, as previously described
for the TEM assay. Before adding the PBMCs to the
HUVECs, the PBMCs were incubated on ice for 15 minutes
with the indicated antibody. The cells were then centrifuged
at 235  g for 5 minutes and washed three times with
M199/0.1% HSA to remove unbound antibody. PBMCs
were then resuspended in M199/0.1% HSA at 2  106
PBMCs/mL and added to the HUVECs for the TEM assay,
as previously described, except that leukocytes were
allowed to migrate for 30 minutes instead of 1 hour.
Endothelial-Side Function Studies
HUVECs were treated with 20 mg/mL of the indicated
antibody in M199/0.1% HSA and incubated at either 4C or
37C for 1 hour. Monolayers were then washed extensively
with M199/0.1% HSA before the addition of PBMCs. TEM
was then allowed to proceed as previously described, except
that leukocytes were allowed to migrate for 30 minutes
instead of 1 hour.
Sequential Blockade of TEM
This procedure was performed as previously described.5
Brieﬂy, the TEM assay was performed exactly as previ-
ously described, except that at the end of the 1-hour incu-
bation at 37C, instead of washing and ﬁxing cells, the
plates were chilled for 30 minutes, washed several times
with cold PBS, and new 20 mg/mL antibody dilutions in
M199/0.1% HSA were added to the samples. Plates were
then warmed, and TEM was allowed to proceed for an
additional 2 hours (previously shown to be sufﬁcient for
recovery from the initial blockade5). TEM was then stopped
by ﬁxing the samples, and the migration was quantiﬁed as
previously described.
Statistical Analysis
All experiments with quantitation were performed inde-
pendently at least three times with at least three replicates
for each sample within each experiment. For the trans-
migration assays, the values for the replicates were averaged
together within each experiment. The average and SD ofajp.amjpathol.org - The American Journal of Pathology
Figure 1 Shp-2 localizes to endothelial cell junctions on PVR stimu-
lation. HUVEC monolayers were treated with 20 mg/mL non-speciﬁc mouse
IgG (ns-mIgG), antibody against PVR, or DNAM-1-Fc chimera for 20 minutes
at 37C and ﬁxed. PECAM and Shp-2 were visualized using ﬂuorescent
antibodies against the indicated protein. Data are representative of four
independent experiments. Scale bar Z 25 mm.
PVR, PECAM, CD99, and Diapedesisthese averages are shown in the ﬁgures. P values for each
experimental condition were calculated from the average
values using the Student’s t-test for unpaired observations
relative to the non-blocking or non-speciﬁc antibody
controls. All P values noted by an asterisk were < 0.05, and
most were < 0.01.
Results
PVR Stimulation Recruits Shp-2
In agreement with published data, we conﬁrm that PVR is
expressed on monocytes and endothelial cells, whereas
DNAM-1 is expressed on monocytes but not on endothelial
cells (Supplemental Figure S1A).7,21 In addition, PVR is
localized to endothelial cell junctions in a manner similar to
PECAM and CD99 (Supplemental Figure S1B). Both
PECAM and PVR contain an immunoreceptor tyrosi-
neebased inhibitory motif (ITIM), a domain that has been
reported to be phosphorylated on ligand stimulation by Src
family kinases. This phosphorylation leads to the recruit-
ment of protein tyrosine phosphatases and is critical for the
signal functions of the proteins that contain the ITIM.
Indeed, tyrosine 686 of the ITIM of PECAM has been
shown to be phosphorylated and to recruit the phosphatase,
Shp-2.33e35 Although the role of phosphorylation of PVR in
TEM is presently unknown, the phosphorylation of the
ITIM of PVR and the recruitment of Shp-2 has been found
to be crucial for the entry of poliovirus into cells.16,17 In
light of these ﬁndings, we hypothesized that PVR phos-
phorylation and Shp-2 recruitment could be involved in
TEM in a mechanism analogous to PECAM and sought to
determine whether ligation of PVR recruits Shp-2 in
primary endothelial cells. In HUVECs under resting con-
ditions or on treatment with an irrelevant antibody, most of
the Shp-2 is distributed diffusely throughout the cytosol,
with only a small fraction found near intercellular junctions
(Figure 1). On treatment with either anti-PVR or a DNAM-
1-Fc chimera, Shp-2 showed a dramatic redistribution to the
junctions (Figure 1).
Shp-2 Recruitment to Coated Beads
Although this redistribution is striking, the stimulation of
adhesion molecules that occurs during TEM is not global;
instead, it is much more spatially restricted to the area in
contact with the leukocyte. Our attempts to examine Shp-2
recruitment to migrating leukocytes were complicated by
the presence of Shp-2 in the leukocyte. Also, because Shp-2
is known to be involved in other steps during TEM,33,36 we
could not distinguish the PVR-speciﬁc recruitment from
recruitment mediated by other receptors (data not shown).
To investigate the speciﬁc Shp-2 recruitment after PVR
stimulation, we stimulated a leukocyte using beads coated
with appropriate ligands. HUVECs were treated with
polystyrene beads that were conjugated with non-speciﬁcThe American Journal of Pathology - ajp.amjpathol.orgmouse IgG, DNAM-1-Fc chimera, or antibodies against
PVR or PECAM. When HUVECs were incubated with
beads coated with non-speciﬁc mouse IgG, only a few beads
(approximately 10%) showed even a modest increase in the
amount of Shp-2 in the adjacent cytoplasm (ie, an increase
in ﬂuorescence intensity of approximately 1.5 times that of
the neighboring cytoplasm) (Figure 2). The incubation of
HUVECs with beads conjugated to ligands known to
stimulate PVR led to an increase in both the intensity of
Shp-2 in the area surrounding the bead and the frequency of
beads with enrichment (approximately 50%). Although
several different incubation times were tested, the number of
beads with enriched Shp-2 never reached 100%, a ﬁnding
that likely indicates the variable amount of time required for
the beads to settle and the transient nature of the Shp-2/PVR
interaction. This enrichment was the result of speciﬁc Shp-2
recruitment and not a generic volume effect of increased
cytosol around the bead because no enrichment of the
housekeeping protein, glyceraldehyde-3-phosphate dehy-
drogenase, was observed around the bead (data not shown).
Also, only minimal and rare enrichment was observed with
beads coated with antibodies against major histocompati-
bility complex class I (data not shown), suggesting that the
recruitment is not simply to a bead interacting with the
endothelial cells. Stimulation of PECAM has also been
shown to recruit Shp-2.33e35 As expected, anti-PECAM
beads recruited Shp-2 in a manner similar to antiePVR-
coated beads (Figure 2) and also recruited PECAM, which
could be detected using a different antibody against PECAM.1035
Figure 2 Shp-2 recruitment to coated beads. A: HUVEC monolayers were
exposed to polystyrene beads coated with non-speciﬁc mouse IgG (ns-mIgG),
DNAM-1-Fc chimera,or antibodiesagainstPVRorPECAMfor20minutesandﬁxed.
Shp-2 andPECAMwere visualizedusing immunoﬂuorescence, as indicated.Beads
for the corresponding images were visualized using bright ﬁeld microscopy.
Arrows, beads with Shp-2 recruitment. Shp-2 recruitment around beads was
variable, dependingon its positionon the cell engagedand the lengthof time the
beadhadbound. ScalebarZ10mm.B: Thenumberof beads showingenrichment
of Shp-2 ﬂuorescence, as seen in A, was scored from ﬁve experiments in which
approximately 50 beads were scored at random for each sample. Enrichment was
deﬁned as those beads with at least a 1.5-fold increase in intensity in the area
immediately surrounding the bead of that compared with the surrounding
cytosol. Data shown are the mean and SD from ﬁve independent experiments.
*P < 0.05, determined using the Student’s t-test for unpaired observations.
Sullivan et alFor experiments with antiePVR-coated beads, we were
unable to check for the recruitment of PVR because of
experimental limitations. As an added control, we also
performed experiments using microspheres of a different1036material (glass) coated with antibodies or DNAM-1-Fc.
As expected, Shp-2 was similarly recruited in a manner
dependent on PVR activation, which shows that the re-
cruitment is not an artifact of the bead composition or
labeling (Figure 3).
Experiments performed in ﬁbroblasts showed that Shp-2 is
recruited to PVR after Src-mediated phosphorylation of Y398
in the ITIMmotif of PVR.17 To see if Shp-2 recruitment in our
system is also dependent on Src kinases, we treated HUVECs
with the Src family inhibitor, PP2. After treatment with PP2,
Shp-2 recruitment to anti-PVR or DNAM-1-Fcecoated
beads (Figure 3) was reduced to baseline levels. Treatment
with the inactive analogue, PP3, had no effect, conﬁrming
that Src family kinases play a role in Shp-2 recruitment
(Figure 3).
Shp-2 Interacts with Phosphorylated PVR
The experiments with coated beads show that the recruit-
ment of Shp-2 is dependent on PVR stimulation and phos-
phorylation by Src kinases. However, it is possible that
Shp-2 is being targeted to some other protein instead of
directly interacting with PVR. To further examine this, we
immunoprecipitated PVR from HUVECs after treatment
with antibodies against PVR, DNAM-1-Fc, or non-speciﬁc
mouse IgG. Commercially available anti-PVR antibodies do
not work well in Western blot analyses; thus, to detect PVR,
we chilled the monolayers and biotinylated all surface
proteins with a membrane-impermeant reagent after the
antibody stimulation but before cell lysis. PVR could then
be immunoprecipitated with anti-PVR antibodies and de-
tected on the blot using streptavidin-HRP (Figure 4).
Treatment of HUVECs with either anti-PVR antibodies or
DNAM-1-Fc induced a signiﬁcant increase in the amount of
phosphorylated PVR. On the same blots, we could detect
the co-immunoprecipitation of Shp-2 with phosphorylated
PVR. Both the phosphorylation of PVR and its interaction
with Shp-2 were inhibited by the Src kinase inhibitor, PP2,
further indicating that Shp-2 binds directly to PVR in an
Src-mediated, phosphorylation-dependent manner.
PVR and DNAM-1 Function in TEM at a Step in between
PECAM and CD99
To investigate the possible connection between PVR,
PECAM, and CD99, we investigated the timing of the roles
of these proteins during TEM. Toward this end, we used an
in vitro assay that is distinct from the one used by Reymond
et al.7 Thus, it was important to conﬁrm the role of these
molecules in our standard TEM assay using HUVECs
grown on hydrated collagen gel matrices. As described in
Materials and Methods, PBMCs were incubated on con-
ﬂuent HUVEC monolayers for 1 hour at 37C in the con-
tinuous presence of the indicated monoclonal antibodies.
During this time, monocytes settle on and cross the endothelial
monolayer unless the antibody disrupts a critical protein-proteinajp.amjpathol.org - The American Journal of Pathology
Figure 3 Shp-2 recruitment is dependent on Src kinase. A: Shp-2
recruitment to coated glass beads was visualized, as in Figure 2, in the
presence of 5 mmol/L Src kinase inhibitor, PP2, or 5 mmol/L inactive inhibitor
analogue, PP3. Beads were coated with the indicated proteins in addition to
a small amount of ﬂuorescently labeled non-speciﬁc antibodies to aid in
their visualization using immunoﬂuorescence (IF). Arrows, beads with Shp-2
recruitment. Data are representative of three independent experiments.
Scale bars: 10 mm. B: The number of beads with enrichment was determined,
as in Figure 2B. Data shown are the mean and SD from three independent
experiments. *P < 0.01. ns-mIgG, non-speciﬁc mouse IgG.
PVR, PECAM, CD99, and Diapedesisinteraction required for TEM. In samples incubated with a non-
blocking antibody (antieVE-cadherin), transmigration pro-
ceeded uninhibited to a maximal 80%. Conﬁrming previous
reports, transmigration was signiﬁcantly reduced in the pres-
ence of antibodies against PECAM and CD99,3,5,7,37 and also
by antibodies against PVR and DNAM-17 (Supplemental
Figure S2A). Approximately 20% of the monocytes in these
samples were able to overcome the antibody blockade, as has
been reported for PECAM,27,30,37 CD99,5,38 and PVR and
DNAM-1.7,8 The inhibition of TEM was not signiﬁcantly
altered when the samples were incubated simultaneously with
any combination of two antibodies (Supplemental Figure S2B).
None of the antibody treatments had a signiﬁcant effect on the
total number of leukocytes able to adhere to the monolayers
(data not shown), suggesting that these observations are due
solely to the ability of these antibodies to block TEM.
To dissect the order of the interactions that facilitate
diapedesis, we exploited the fact that antibody blockade ofThe American Journal of Pathology - ajp.amjpathol.orgTEM is reversible if the blocking antibody is washed away
and samples are given additional time (>1 hour) to undergo
transmigration.4,5 If a new antibody is added during this
later incubation, TEM will only continue to be blocked if
the leukocytes have not already passed the step mediated
by the second targeted molecule.5 Thus, by performing two
sequential rounds of treatment with different antibody com-
binations, we can determine the order in which the different
proteins function during TEM. As seen in Figure 5A, the
initial antibody treatments that effectively blocked TEM
(Supplemental Figure S2B) could be reversed by washing
out the antibody and allowing TEM to proceed for an
additional 2 hours. When the same antibody was added
back for the second incubation, TEM remained blocked,
demonstrating that the monocytes do not overcome the
blockade solely by prolonged incubation (Figure 5B).
By using this assay, we have already shown that PECAM
and CD99 act sequentially in TEM.5 As previously shown
and reconﬁrmed herein, blocking PECAM during the ﬁrst
incubation and CD99 during the second incubation result in
an effective block of TEM that is comparable to continuous
treatment with either antibody treatment alone (Figure 5C).
Conversely, blocking CD99 ﬁrst and PECAM second
resulted in no blockade, consistent with PECAM acting
upstream of CD99.5
To determine where PVR and DNAM-1 function in TEM
relative to PECAM and CD99, we performed a similar
analysis using sequential incubations of several combina-
tions of antibodies against PVR and DNAM-1, in addition
to PECAM and CD99 (Figure 5C). In all of the samples in
which the initial incubation was with anti-PECAM anti-
bodies (Figure 5C), TEM was signiﬁcantly reduced, sug-
gesting that PVR, DNAM-1, and CD99 all function in
TEM at steps later than the step at which PECAM functions.
This was conﬁrmed by the observation that TEM was not
blocked in any sample (including those treated with antie
DNAM-1 and anti-PVR) in which anti-PECAM antibodies
were added only during the second incubation. The opposite
ﬁndings were obtained when the initial incubations were
with antibodies against CD99 (Figure 5C), indicating that
CD99 functions after PECAM, PVR, and DNAM-1. These
data place PVR and DNAM-1 function in between the
activities of PECAM and CD99. Interestingly, regardless of
their order, treatment with antibodies against PVR and
DNAM-1 produced the same blockade, an observation that
is consistent with PVR and DNAM-1 interacting at the
same step in TEM. To conﬁrm that these ﬁndings are not
unique to large-vessel endothelial cells (HUVECs), we
repeated the sequential TEM using primary HMVECs. As
expected, PECAM, PVR/DNAM-1, and CD99 all acted in
the same order as in HUVECs, further conﬁrming the
sequential nature of these molecules during transmigration
(Supplemental Figure S3). When taken together, these data
support the model that PVR interacts with DNAM-1 during
TEM at a step between the one controlled by PECAM and
the one controlled by CD99.1037
Figure 4 Shp-2 interaction with PVR is dependent on Src kinase. HUVEC
monolayers were treated with non-speciﬁc mouse IgG (ns-mIgG), antibody
against PVR, or DNAM-1-Fc chimera in the presence of Src kinase inhibitor,
PP2, or the inactive inhibitor analogue, PP3, as indicated. Monolayers were
then chilled, labeled with biotin, and lysed. PVR was immunoprecipitated
and visualized using streptavidin conjugated to HRP. Coprecipitated
proteins were visualized using corresponding antibodies, as detailed in
Materials and Methods. Data are representative of three independent
experiments.
Sullivan et alOnly the PVR on the Endothelial Cells Is Functionally
Active in TEM
Although PVR is clearly involved in diapedesis (Figure 5
and Supplemental Figure S2), the expression of PVR on
both HUVECs and monocytes (Supplemental Figure S1)
raises the question of which cell type bears the PVR that is
relevant to TEM. To distinguish between these different
populations of PVR, we pre-incubated each cell type with
the indicated antibodies individually. The cells were then
washed extensively, and TEM assayed as before, except that
the incubation was shortened to 30 minutes, conditions that
were previously shown to maintain the initial blockade in
the absence of excess antibody in solution4,5 (Figure 6A).
Consistent with our prior observations, pre-incubation of
either HUVECs or PBMCs with antibodies against PECAM
or CD99 signiﬁcantly reduced TEM.4,5 TEM was also
inhibited by pre-incubating HUVECs with antibodies
against PVR or treating PBMCs with antibodies against
DNAM-1. On the other hand, no blockade was seen when
HUVECs were incubated with antibodies against DNAM-1
or when PBMCs were pre-incubated with antibodies against
PVR.
As an additional control, we incubated monocytes and
endothelial cells that had each been differentially, but
simultaneously, treated with antibodies against PVR and
DNAM-1 and washed before assaying TEM (Figure 6B). As
expected, TEM was not inhibited when monocytes were
pretreated with anti-PVR antibody and endothelial cells
were pretreated with antieDNAM-1. However, TEM was
inhibited by blockade of monocyte DNAM-1 and endothe-
lial cell PVR, and the blockade was no better than that ob-
served when either protein was blocked individually, further
supporting a direct functional interaction during TEM
between endothelial cell PVR and monocyte DNAM-1.1038PVR Is in the LBRC
PECAM and CD99 have both been shown to reside in the
LBRC. Because PVR acts between these two, we reasoned
that a subpopulation of PVR might also reside in the LBRC.
It has been shown that PECAM in the LBRC is sequestered
from extracellular reagents during treatment at 4C, and it is
this protected pool of PECAM that functions in TEM.5 To
determine whether PVR is similarly sequestered, HUVECs
were pretreated with anti-PVR antibody at either 4C or
37C and rinsed extensively before the addition of PBMCs.
In contrast to treatment at 37C, TEM was not inhibited
when HUVECs were pretreated at 4C with antibodies
against PVR (Figure 7A), suggesting that the functional
pool of PVR also resides in the LBRC in a manner analo-
gous to PECAM and CD99.
To examine this more directly, we analyzed the subcel-
lular distribution of PVR using immunoelectron micros-
copy. Images obtained from HUVECs labeled at 37C with
HRP-conjugated anti-PVR antibody (Figure 7B) show the
unique interconnected tubulovesicular structures that are
characteristic of the LBRC, morphologically indistinguish-
able from staining with anti-PECAM antibodies (Figure 7C)
and in contrast to staining for VE-cadherin, a junctional
protein that is known to be excluded from the LBRC.39 In
addition, incubating HUVECs with anti-PVR antibodies at
4C only labeled the junctions and not the LBRC
(Figure 7C). Under these conditions, unlabeled LBRC was
visible, further demonstrating the exclusion of the antibody
from this compartment at 4C and indicating that the lack of
LBRC staining is not a sampling issue (Figure 7C). This
temperature-sensitive differential labeling has only been
reported for other conﬁrmed LBRC proteins and further
demonstrates that PVR is also in the LBRC.Discussion
Leukocyte extravasation involves sequential steps of teth-
ering, rolling, activation, adhesion, locomotion, and diape-
desis, each involving the interaction of different molecules
on the leukocyte and endothelial surfaces.40,41 The process
of diapedesis, in which the leukocyte migrates between two
tightly apposed endothelial cells into the site of inﬂamma-
tion, has been shown to involve the sequential roles of two
separate molecules, PECAM and CD99, each separately
interacting in a homophilic manner between the leukocyte
and endothelial cell.5 Herein, we conﬁrm that the molecules
PVR and DNAM-1 also act in diapedesis, and that they act
together at the same step. Prior studies have shown that
these molecules form a ligand-receptor pair,7,8,11,16 a feature
in contrast to the homophilic intercellular interactions of
PECAM and CD99. Our new studies contribute several
novel ﬁndings: i) similar to PECAM, endothelial PVR
engagement and subsequent phosphorylation recruit Shp-2
to the site of interaction; ii) the process of TEM can beajp.amjpathol.org - The American Journal of Pathology
PV
R
DN
AM
-1
PE
CA
M
CD
99_
No
n-
blo
cki
ng
0%
20%
40%
60%
80%
TE
M
PV
R
DN
AM
-1
PE
CA
M
CD
99_
No
n-
blo
cki
ng
0%
20%
40%
60%
80%
TE
M
* * * *
Antibody treatment
Antibody treatment
CD
99
PV
R
DN
AM
-1
PE
CA
M
0%
20%
40%
60%
80%
PECAM CD99PVR DNAM-1
1st antibody
PV
R
DN
AM
-1
CD
99
DN
AM
-1
PE
CA
M
CD
99
PE
CA
M
PV
R
2nd antibody
TE
M
* * * **
* *
Figure 5 Sequential blockade of TEM. The TEM of PBMCs through HUVEC
monolayers was assayed in the absence or continuous presence of anti-
bodies, as described in Materials and Methods for sequential antibody
incubations. Samples were initially incubated with antibodies against the
indicated molecules, as described for the standard TEM assay. Samples were
then chilled, washed extensively, warmed, and subjected to a second
incubation in the presence of antibodies (A), the same antibody used for
the initial incubation (B), or an antibody against a different protein (C).
After the second incubation, the samples were ﬁxed and the TEM was
quantiﬁed. Data represent the mean of at least four replicates from at least
three different experiments. All of the samples for AeC were performed in
parallel but are shown separately for clarity. Error bars represent SDs. *P <
0.05, determined using the Student’s t-test for unpaired observations.
PVR, PECAM, CD99, and Diapedesismolecularly dissected into at least three steps; iii) the
interaction of leukocyte DNAM-1 with endothelial cell PVR
regulates an intermediate step (between those controlled by
PECAM and CD99) for monocyte TEM; iv) such asThe American Journal of Pathology - ajp.amjpathol.orgPECAM and CD99, PVR resides in the LBRC; and v) it is
the fraction of PVR molecules that reside in the LBRC that
is critical for TEM. A potential common theme emerges
from this work that the LBRC may be a shared membrane
platform on which the molecules that regulate TEM are
arrayed to perform their functions. For at least PECAM and
PVR, this common function also involves recruiting Shp-2.
Acquiring these data depended on the reversible blockade
of speciﬁc required protein-protein interactions. Anti-
PECAM, anti-CD99, and anti-PVR arrest TEM for as
long as they are present. Once excess antibody is removed,
however, processing of bound antibody on the endothelial
cell and leukocyte ensues and concentrations decrease lower
than the critical level for blockade of cognate molecules
within approximately 1 hour, allowing TEM to resume. If
a different blocking antibody is added during this time,
however, that antibody is capable of binding its ligand and
potentially halting the recovery of TEM. In this way,
PECAM, CD99, and PVR could all be blocked separately
and in a particular order. When one molecule (eg, PECAM)
functions upstream of another (eg, PVR), blockade of the
upstream molecule can be lifted and replaced with blockade
of the downstream molecule, resulting in retained inhibition
of TEM. If blocked in the reverse order, however, TEM is
not inhibited when the block of the downstream molecule
is lifted because the leukocyte has already migrated past the
step that is regulated by the upstream molecule. In addition,
sequential treatments using PVR and DNAM-1 antibodies
inhibited TEM, regardless of the order of the treatments
(Figure 5C), a ﬁnding that is only consistent with DNAM-1
and PVR functioning at the same step in TEM.
The LBRC is a subjunctional reticulum composed of
interconnected 50-nm vesicle-like structures that are con-
tiguous with the plasma membrane, distinct from caveolae,
and not accessible to extracellular antibodies at 4C.3 Data
presented herein show that PVR localizes to the LBRC,
similar to PECAM and CD99 (Figure 7). Based on the
similar morphological characteristics of the PVR-containing
structures and the PECAM-containing LBRC (Figure 7B)
and the similar 4C protection of PVR, PECAM, and CD99
(Figure 6A), it is likely that PVR colocalizes in the LBRC
with PECAM and CD99, rather than being segregated into
distinct subsections. This is further supported by the ﬁnding
that PVR functions a step between PECAM and CD99
(Figure 5C).
We have previously shown that this compartment recy-
cles to surround migrating leukocytes, and we hypothesize
that this targeted movement of the LBRC could serve to
deliver unligated adhesion molecules for critical interactions
and signals to promote TEM and provide additional
membrane surface area to accommodate the migrating
leukocyte, which would be particularly required for trans-
cellular TEM.3,39 Thus, the LBRC could function as both
a delivery mechanism and a storage compartment for
proteins that facilitate TEM. Together, these data support
a model in which the functionally active pools of PECAM,1039
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Figure 6 Cell typeespeciﬁc blockade of TEM. A: HUVECs or PBMCs were
pre-incubated with antibodies against the indicated molecules before being
washed and used in the standard TEM assay (as described in Materials and
Methods). B: TEM was assayed in samples in which HUVECs (treated at 37C)
and PBMCs (treated at 4C) were differentially treated with either anti-
bodies against PVR or DNAM-1, as indicated; both cell types were washed
extensively before the TEM assay. The data shown in A and B are from the
same experiments; they are separated into two graphs for clarity. Data
represent the mean of at least three replicates from at least three inde-
pendent experiments. Error bars represent SDs. *P < 0.05, determined
using the Student’s t-test for unpaired observations.
Figure 7 LBRC localization of PVR. A: The standard TEM assay was
performed as described in Materials and Methods, except that HUVECs were
pretreated for 45 minutes with antibodies against the indicated molecules
at 4C or 37C. Monolayers were then washed at 4C to remove unbound
antibodies before adding PBMCs and continuing with the standard assay. B
and C: HUVEC monolayers treated with HRP-conjugated antibodies, as
indicated at either 4C or 37C, were processed for immuno-EM, as
described in Materials and Methods. Black arrows, LBRC-interconnected
vesicles visualized by diaminobenzidene staining; white arrows, likely
unstained LBRC vesicles. Scale bars: 500 nm (B and C).
Sullivan et alPVR, and CD99 are all localized to the LBRC so that they
may be targeted to the transmigrating leukocyte together.
Shp-2 has been shown to interact with PVR in other
systems.16,17 Herein, we show that the two interact in
a stimulus-dependent, Src kinaseedependent mechanism
in primary endothelial cells. Data from ﬁbroblasts suggest
that this interaction occurs through phosphorylation of the
ITIM domain of PVR.17 Interestingly, Shp-2 has also been
shown to bind to the phosphorylated ITIM motif of1040PECAM.33e35 The respective roles of PECAM and PVR in
this process, and the exact role of Shp-2, are areas of
ongoing research. We hypothesized that PECAM stimula-
tion could somehow affect the timing or amount of Shp-2
that interacts with PVR, perhaps by priming PVR to
accept Shp-2. However, no signiﬁcant change was observedajp.amjpathol.org - The American Journal of Pathology
PVR, PECAM, CD99, and Diapedesisin the kinetics or amount of Shp-2 association with PVR on
prior or continuous stimulation of PECAM (data not
shown). This could suggest that PVR and PECAM each
require Shp-2 separately for their individual downstream
signaling. Alternatively, it is possible that the recruitment of
Shp-2 by PECAM, PVR, and/or other junctional proteins
could serve to increase Shp-2 concentration in the area of
transmigration to a critical threshold that, by itself, could be
an important signal. Perhaps Shp-2 is recruited to the
junction to turn off several of the signaling cascades initi-
ated by leukocyte interaction. Indeed, the entire diapedesis
process is initiated and completed within a few minutes.
During this time, several receptors and signaling molecules
are rapidly activated.2,42 It is likely that the endothelial cell
would need to rapidly down-regulate or turn off these
activated receptors and signals, possibly to preserve junc-
tional integrity or to reset the mechanism for additional
rounds of TEM.
One interesting observation of this study is the apparent
paradox regarding how the D171 antibody (anti-PVR) can
simultaneously stimulate PVR and block transmigration.
Evidence from other studies suggests that antibody-mediated
blockades/treatments often have this sort of result (ie, acti-
vation of the molecule but disruption of its function). Indeed,
anti-PECAM antibody had the same effect (Figure 25,6).
Although it is tempting to speculate that the only relevant
result of PVR activation is the recruitment of Shp-2, in reality
the process is likely to be much more complex. Indeed, the
observation that theD171 antibody is able to recruit Shp-2 but
still blocks TEM (a ﬁnding observed in part by other
groups7,8) suggests that the recruitment of Shp-2 is not the
sole function of PVR. This disconnect could be the result of
altered spatiotemporal regulation of the target molecule. In
other words, the molecule is stimulated, but not at the right
time or location to elicit the desired outcome. Extrapolation of
these ﬁndings to our study strongly suggests that D171 is
activating PVR, leading to phosphorylation and Shp-2
recruitment; however, because this stimulation does not
occur in the precise order and timing required for trans-
migration, the whole TEM process is disrupted and the
leukocytes cannot migrate efﬁciently. Furthermore, this
antibody treatment also blocks the interaction of PVRwith its
obligate binding partner, DNAM-1, thus preventing the
reciprocal activation of DNAM-1 on the leukocyte, which
could likely be an equally important signaling event during
TEM. Indeed, this sort of antibody-mediated disruption,
including Src-mediated phosphorylation and Shp-2 recruit-
ment, has been reported for anti-PECAM antibody treatment,
and additional data suggest that this is the mechanism by
which antibody treatments can be used to disrupt extravasa-
tion at several different steps both in vivo and in vitro.
This elucidation of the mechanism of PVR and DNAM-1
function during TEM adds to the increasing information
about the growing number of molecules involved in the
process of diapedesis. One might envision that the relative
roles of the different receptors and the different signalingThe American Journal of Pathology - ajp.amjpathol.orgmechanisms may vary based on the context (ie, the site of
inﬂammation and the nature of the stimulus) and, in fact,
data already exist to suggest such differential regulation of
TEM.43e46 Alternately, these mechanisms may introduce
a system of potential redundancy that would ensure that an
evolutionarily essential process continues, even in the face
of partial inhibition. Thus, understanding how the various
molecules can potentially mediate TEM function will be
essential to effective treatment. Ultimately, the complete
understanding of these mechanisms will be essential to
facilitate therapeutic intervention into hypoinﬂammatory
and hyperinﬂammatory conditions in highly speciﬁc ways,
without global disruption of immune function.
Acknowledgments
We thank Clifford D. Carpenter and Ron Liebman for
assistance with experiments; Drs. Oliver Florey, Gong Feng,
Fei Han, and Sumana Sanyal for insightful discussions; and
Begum Kutay for thoughtful review of the manuscript.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2012.11.037.
References
1. Muller WA: Mechanisms of transendothelial migration of leukocytes.
Circ Res 2009, 105:223e230
2. Muller WA: Mechanisms of leukocyte transendothelial migration.
Annu Rev Pathol 2011, 6:323e344
3. Mamdouh Z, Chen X, Pierini LM, Maxﬁeld FR, Muller WA: Targeted
recycling of PECAM from endothelial cell surface-connected
compartments during diapedesis. Nature 2003, 421:748e753
4. Muller WA, Weigl SA, Deng X, Phillips DM: PECAM-1 is required
for transendothelial migration of leukocytes. J Exp Med 1993, 178:
449e460
5. Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA: CD99
plays a major role in the migration of monocytes through endothelial
junctions. Nat Immunol 2002, 3:143e150
6. Schenkel AR, Chew TW, Muller WA: Platelet endothelial cell adhe-
sion molecule deﬁciency or blockade signiﬁcantly reduces leukocyte
emigration in a majority of mouse strains. J Immunol 2004, 173:
6403e6408
7. Reymond N, Imbert AM, Devilard E, Fabre S, Chabannon C, Xerri L,
Farnarier C, Cantoni C, Bottino C, Moretta A, Dubreuil P, Lopez M:
DNAM-1 and PVR regulate monocyte migration through endothelial
junctions. J Exp Med 2004, 199:1331e1341
8. Manes TD, Pober JS: Identiﬁcation of endothelial cell junctional
proteins and lymphocyte receptors involved in transendothelial
migration of human effector memory CD4þ T cells. J Immunol 2011,
186:1763e1768
9. Bernhardt G, Bibb JA, Bradley J, Wimmer E: Molecular character-
ization of the cellular receptor for poliovirus. Virology 1994, 199:
105e113
10. Mendelsohn CL, Wimmer E, Racaniello VR: Cellular receptor for
poliovirus: molecular cloning, nucleotide sequence, and expression of
a new member of the immunoglobulin superfamily. Cell 1989, 56:
855e8651041
Sullivan et al11. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B,
Cantoni C, Grassi J, Marcenaro S, Reymond N, Vitale M, Moretta L,
Lopez M, Moretta A: Identiﬁcation of PVR (CD155) and Nectin-2
(CD112) as cell surface ligands for the human DNAM-1 (CD226)
activating molecule. J Exp Med 2003, 198:557e567
12. Freistadt MS, Eberle KE: Physical association between CD155 and
CD44 in human monocytes. Mol Immunol 1997, 34:1247e1257
13. Koike S, Horie H, Ise I, Okitsu A, Yoshida M, Iizuka N, Takeuchi K,
Takegami T, Nomoto A: The poliovirus receptor protein is produced
both as membrane-bound and secreted forms. EMBO J 1990, 9:
3217e3224
14. Ohka S, Ohno H, Tohyama K, Nomoto A: Basolateral sorting of
human poliovirus receptor alpha involves an interaction with the mu1B
subunit of the clathrin adaptor complex in polarized epithelial cells.
Biochem Biophys Res Commun 2001, 287:941e948
15. Mueller S, Wimmer E, Cello J: Poliovirus and poliomyelitis: a tale of
guts, brains, and an accidental event. Virus Res 2005, 111:175e193
16. Coyne CB, Kim KS, Bergelson JM: Poliovirus entry into human brain
microvascular cells requires receptor-induced activation of SHP-2.
EMBO J 2007, 26:4016e4028
17. Oda T, Ohka S, Nomoto A: Ligand stimulation of CD155alpha inhibits
cell adhesion and enhances cell migration in ﬁbroblasts. Biochem
Biophys Res Commun 2004, 319:1253e1264
18. Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M: Cutting edge:
CD96 (tactile) promotes NK cell-target cell adhesion by interacting with
the poliovirus receptor (CD155). J Immunol 2004, 172:3994e3998
19. Lange R, Peng X, Wimmer E, Lipp M, Bernhardt G: The poliovirus
receptor CD155 mediates cell-to-matrix contacts by speciﬁcally
binding to vitronectin. Virology 2001, 285:218e227
20. Mueller S, Wimmer E: Recruitment of nectin-3 to cell-cell junctions
through trans-heterophilic interaction with CD155, a vitronectin and
poliovirus receptor that localizes to alpha(v)beta3 integrin-containing
membrane microdomains. J Biol Chem 2003, 278:31251e31260
21. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K,
McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL,
Phillips JH: DNAM-1, a novel adhesion molecule involved in the
cytolytic function of T lymphocytes. Immunity 1996, 4:573e581
22. Sherrington PD, Scott JL, Jin B, Simmons D, Dorahy DJ, Lloyd J,
Brien JH, Aebersold RH, Adamson J, Zuzel M, Burns GF: TLiSA1
(PTA1) activation antigen implicated in T cell differentiation and
platelet activation is a member of the immunoglobulin superfamily
exhibiting distinctive regulation of expression. J Biol Chem 1997, 272:
21735e21744
23. Jia W, Liu XS, Zhu Y, Li Q, Han WN, Zhang Y, Zhang JS, Yang K,
Zhang XH, Jin BQ: Preparation and characterization of mabs against
different epitopes of CD226 (PTA1). Hybridoma 2000, 19:489e494
24. Chen L, Xie X, Zhang X, Jia W, Jian J, Song C, Jin B: The expression,
regulation and adhesion function of a novel CD molecule, CD226, on
human endothelial cells. Life Sci 2003, 73:2373e2382
25. Shibuya K, Shirakawa J, Kameyama T, Honda S, Tahara-Hanaoka S,
Miyamoto A, Onodera M, Sumida T, Nakauchi H, Miyoshi H,
Shibuya A: CD226 (DNAM-1) is involved in lymphocyte function-
associated antigen 1 costimulatory signal for naive T cell differentia-
tion and proliferation. J Exp Med 2003, 198:1829e1839
26. Kojima H, Kanada H, Shimizu S, Kasama E, Shibuya K, Nakauchi H,
Nagasawa T, Shibuya A: CD226 mediates platelet and megakaryocytic
cell adhesion to vascular endothelial cells. J Biol Chem 2003, 278:
36748e36753
27. Mamdouh Z, Kreitzer GE, Muller WA: Leukocyte transmigration
requires kinesin-mediated microtubule-dependent membrane trafﬁcking1042from the lateral border recycling compartment. J Exp Med 2008, 205:
951e966
28. Muller WA, Ratti CM, McDonnell SL, Cohn ZA: A human endothelial
cell-restricted, externally disposed plasmalemmal protein enriched in
intercellular junctions. J Exp Med 1989, 170:399e414
29. Ali J, Liao F, Martens E, Muller WA: Vascular endothelial cadherin
(VE-cadherin): cloning and role in endothelial cell-cell adhesion.
Microcirculation 1997, 4:267e277
30. Liao F, Ali J, Greene T, Muller WA: Soluble domain 1 of platelet-
endothelial cell adhesion molecule (PECAM) is sufﬁcient to block trans-
endothelialmigration invitro and invivo. JExpMed1997, 185:1349e1357
31. Muller WA, Luscinskas FW: Assays of transendothelial migration
in vitro. Methods Enzymol 2008, 443:155e176
32. Muller WA, Weigl S: Monocyte-selective transendothelial migration:
dissection of the binding and transmigration phases by an in vitro
assay. J Exp Med 1992, 176:819e828
33. Dasgupta B, Dufour E, Mamdouh Z, Muller W: A novel and critical
role for tyrosine 663 in PECAM trafﬁcking and transendothelial
migration. J Immunol 2009, 182:5041e5051
34. Newman DK, Hoffman S, Kotamraju S, Zhao T, Wakim B,
Kalyanaraman B, Newman PJ: Nitration of PECAM-1 ITIM tyrosines
abrogates phosphorylation and SHP-2 binding. Biochem Biophys Res
Commun 2002, 296:1171e1179
35. Maas M, Wang R, Paddock C, Kotamraju S, Kalyanaraman B,
Newman PJ, Newman DK: Reactive oxygen species induce reversible
PECAM-1 tyrosine phosphorylation and SHP-2 binding. Am J Physiol
Heart Circ Physiol 2003, 285:H2336eH2344
36. Pluskota E, Chen Y, D’Souza SE: Src homology domain 2-containing
tyrosine phosphatase 2 associates with intercellular adhesion molecule
1 to regulate cell survival. J Biol Chem 2000, 275:30029e30036
37. Muller WA: The role of PECAM-1 (CD31) in leukocyte emigration:
studies in vitro and in vivo. J Leukoc Biol 1995, 57:523e528
38. Lou O, Alcaide P, Luscinskas FW, Muller WA: CD99 is a key
mediator of the transendothelial migration of neutrophils. J Immunol
2007, 178:1136e1143
39. Mamdouh Z, Mikhailov A, Muller WA: Transcellular migration of
leukocytes is mediated by the endothelial lateral border recycling
compartment. J Exp Med 2009, 206:2795e2808
40. Muller WA: Leukocyte-endothelial-cell interactions in leukocyte
transmigration and the inﬂammatory response. Trends Immunol 2003,
24:326e333
41. Ley K, Laudanna C, Cybulsky MI, Nourshargh S: Getting to the site of
inﬂammation: the leukocyte adhesion cascade updated. Nat Rev
Immunol 2007, 7:678e689
42. Kamei M, Carman CV: New observations on the trafﬁcking and dia-
pedesis of monocytes. Curr Opin Hematol 2010, 17:43e52
43. Dangerﬁeld JP, Wang S, Nourshargh S: Blockade of alpha6 integrin
inhibits IL-1beta- but not TNF-alpha-induced neutrophil trans-
migration in vivo. J Leukoc Biol 2005, 77:159e165
44. Nourshargh S, Krombach F, Dejana E: The role of JAM-A and
PECAM-1 in modulating leukocyte inﬁltration in inﬂamed and
ischemic tissues. J Leukoc Biol 2006, 80:714e718
45. Albelda SM, Lau KC, Chien P, Huang Z, Arguiris E, Bohen A, Sun J,
Billet JA, Christoﬁdou-Solomidou M, Indik ZK, Schrieber AD: Role
for platelet-endothelial cell adhesion molecule-1 in macrophage Fcg
receptor function. Am J Respir Cell Mol Biol 2004, 31:246e255
46. Woodﬁn A, Voisin MB, Imhof BA, Dejana E, Engelhardt B,
Nourshargh S: Endothelial cell activation leads to neutrophil trans-
migration as supported by the sequential roles of ICAM-2, JAM-A and
PECAM-1. Blood 2009, 113:6246e6257ajp.amjpathol.org - The American Journal of Pathology
